Sclerostin Expression in Bile Ducts of Patients With Chronic Cholestasis May Influence the Bone Disease in Primary Biliary Cirrhosis
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Sclerostin is involved in the regulation of osteoblastogenesis and little is known about its role in the development of bone disease in primary biliary cirrhosis (PBC), characterized by low bone formation. Therefore, we have assessed the circulating levels and the liver expression of sclerostin in this cholestatic disease. Serum sclerostin levels were measured in 79 women with PBC (mean age 60.6 ± 1.2 years) and in 80 control women. Lumbar and femoral bone mineral density (BMD), as well as parameters of mineral metabolism and bone remodeling, were measured. Moreover, sclerostin gene (SOST) expression in the liver was assessed by real-time PCR in samples of liver tissue taken by biopsy in 11 PBC patients and in 5 normal liver specimens. Presence and distribution of sclerostin was evaluated in liver slices from 11 patients by immunohistochemistry. The severity of histologic lesions was assessed semiquantitatively in the same liver samples. PBC patients had higher sclerostin levels than controls (75.6 ± 3.9 versus 31.7 ± 1.6 pmol/L, p < 0.001). Serum sclerostin correlated inversely with markers of bone formation and resorption. Sclerostin mRNA in the liver was overexpressed compared with control samples (2.7-fold versus healthy liver). Sclerostin was detected by immunohistochemistry in 7 of the 11 liver samples, mainly located in the bile ducts. Liver sclerostin was associated with the severity of cholangitis (p = 0.02) and indirectly with the degree of lobular inflammation (p = 0.03). Sclerostin mRNA expression was higher in samples that tested positive by immunohistochemistry and particularly in those with lobular granuloma (p = 0.02). The increased expression of sclerostin in the liver and the association with histologic cholangitis may explain the high serum levels of this protein in patients with PBC, thus suggesting that sclerostin may influence the decreased bone formation in this cholestatic disease. © 2016 American Society for Bone and Mineral Research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
WNT signaling in bone homeostasis and disease: From human mutations to treatments
Baron, R., & Kneissel, M. (2013) · Nature Medicine · doi:10.1038/nm.3074 · Cited by 2,093
Regulation of bone mass by Wnt signaling
Krishnan, V. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28551 · Cited by 1,407
Sclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling
Li, X., Zhang, Y., Kang, H., Liu, W., Liu, P., Zhang, J., Harris, S. E., & Wu, D. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413274200 · Cited by 1,366
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
Balemans, W. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.5.537 · Cited by 1,147 · cited 2×
“Interestingly, isolated studies have shown that SOST, the gene encoding sclerostin, is also expressed in other tissues such as the cartilage, aorta, kidney, and in small quantities in the liver, among others, when human tissues and cell lines were examined.((24,25)) Furthermore, extraskeletal sources of sclerostin hav…”
BackgroundBrunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y.-H., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318811 · Cited by 1,011 · cited 2×
“highest levels of expression, but SOST low expression was also found in cartilage and adult liver.((24)) Interestingly, Cejka and colleagues found that sclerostin protein was detected in human renal tissue, using immunohistochemistry, predominantly in the proximal tubular cells,((28)) and others have found sclerostin…”
BackgroundSclerostin is a delayed secreted product of osteocytes that inhibits bone formation
Poole, K. E. S., Van Bezooijen, R. L., Loveridge, N., Hamersma, H., Papapoulos, S. E., Löwik, C. W., & Reeve, J. (2005) · The FASEB Journal · doi:10.1096/fj.05-4221fje · Cited by 965
Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)
Ludwig, J., Dickson, E. R., & McDonald, G. S. A. (1978) · Virchows Archiv A Pathological Anatomy and Histology · doi:10.1007/bf00432479 · Cited by 753
Eastell, R., Dickson, R. E., Hodgson, S. F., Wiesner, R. H., Porayko, M. K., Wahner, H. W., Cedel, S. L., Riggs, L. B., & Krom, R. A. F. (1991) · Hepatology · doi:10.1002/hep.1840140215 · Cited by 297 · cited 1×
“This lowbone formationhasbeenassociatedwith an increase in bone resorption at different stages of the liver disease.((4,16)) In the last years, a molecular signaling involving the Wnt/ ß-catenin has emerged as the main regulator of bone mass and osteoblastogenesis.”
BackgroundBone disease in primary biliary cirrhosis: independent indicators and rate of progression
Menon, K. V. N., Angulo, P., Weston, S., Dickson, E. R., & Lindor, K. D. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00144-1 · Cited by 180 · cited 2×
“Osteoporosis and low bone mass are frequent complications of primary biliary cirrhosis (PBC), the main chronic cholestatic liver disease.((1,2)) The overall prevalence of osteoporosis in patients with any sort of chronic liver disease has been reported to be between 12% and 45%.”
BackgroundGuañabens, N., Parés, A., Ros, I., Caballería, L., Pons, F., Vidal, S., Monegal, A., Peris, P., & Rodés, J. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2004.11.035 · Cited by 179 · cited 2×
“In addition, the decreased serum levels of osteocalcin, a bone formationmarker, also point to a diminution of bone formation in these patients.((6,12,13)) Reinforcing these observations, we have found in in vitro studies that unconjugated bilirubin decreases the survival of cultured primary human osteoblasts, and addi…”
BackgroundSelf-citationGuañabens, N., Cerdá, D., Monegal, A., Pons, F., Caballería, L., Peris, P., & Parés, A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.02.016 · Cited by 142
Self-citationNinkovic, M., Love, S. A., Tom, B., Alexander, G. J. M., & Compston, J. E. (2001) · Calcified Tissue International · doi:10.1007/s00223-001-2028-4 · Cited by 123 · cited 1×
“and this prevalence is even higher in patients with an advanced stageof thedisease, close to40%,((4,5))with a riskof fracture around 20% to 25%.”
BackgroundRuiz-Gaspà, S., Martinez-Ferrer, A., Guañabens, N., Dubreuil, M., Peris, P., Enjuanes, A., de Osaba, M. J. M., Alvarez, L., Monegal, A., Combalia, A., et al. (2010) · Hepatology · doi:10.1002/hep.24605 · Cited by 75 · cited 3×
“Afterward, in more advanced liver disease, there is a progressive paucity of bile ducts, and the accumulation of related substances of cholestasis such as bilirubin and bile acids induce a low bone formation state, as has been demonstrated in in vitro studies.((14,15)) Thus, Janes and colleagues showed that bilirubin…”
BackgroundResultSelf-citationGuañabens, N., & Parés, A. (2010) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2010.05.030 · Cited by 71
Self-citationBone histomorphometric changes after liver transplantation for chronic cholestatic liver disease
Guichelaar, M. M., Malinchoc, M., Sibonga, J. D., Clarke, B. L., & Hay, J. E. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.12.2190 · Cited by 50
Effect of liver dysfunction on circulating sclerostin
Rhee, Y., Kim, W. J., Han, K. J., Lim, S. K., & Kim, S. H. (2014) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-013-0524-z · Cited by 42
Serum sclerostin in alcoholics: a pilot study
González-Reimers, E., Martín-González, C., de la Vega-Prieto, M. J., Pelazas-González, R., Fernández-Rodríguez, C., López-Prieto, J., Alvisa-Negrín, J., & Santolaria-Fernández, F. (2013) · Alcohol and Alcoholism · doi:10.1093/alcalc/ags136 · Cited by 41
Cited by
Osteoporosis in chronic liver disease
Guañabens, N., & Parés, A. (2018) · Liver International · doi:10.1111/liv.13730 · Cited by 128
Self-citationJadzic, J., Milovanovic, P. D., Cvetkovic, D., Zivkovic, V., Nikolic, S., Tomanovic, N., Djuric, M. P., & Djonic, D. (2022) · Journal of Anatomy · doi:10.1111/joa.13621 · Cited by 14
“Moreover, increased local sclerostin expression has recently been observed in the liver tissue samples obtained from patients with primary biliary cirrhosis (Guañabens et al., 2016).”
BackgroundMoradi, M., Doustimotlagh, A. H., Dehpour, A. R., Rahimi, N., & Golestani, A. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116706 · Cited by 9
Metadata
- Authors
- Guañabens, N., Ruiz-Gaspà, S., Gifre, L., Miquel, R., Peris, P., Monegal, A., Dubrueil, M., Arias, A., & Parés, A.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-03-27
- Volume
- 31
- Issue
- 9
- Pages
- 1725-1733
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2307018933
- Cited by
- 39
- References
- 18
- FWCI
- 3.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.